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Screening mammography use in older women 
according to health status: a systematic review 
and meta-analysis
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Tomi Akinyemiju3
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Background: The extent to which screening mammography (SM) recommendations in older 
women incorporate life expectancy factors is not well established.
Objective: The objective of this review was to evaluate evidence on SM utilization in older 
women by life expectancy factors.
Data sources: We searched Medline, Embase and Web of Science from January 1991 to 
March 2016.
Study selection: We included studies examining SM utilization in women ages $65 years 
that measured life expectancy using comorbidity, functional limitations or health or prognostic 
status.
Data extraction and synthesis: ORs and 95% CIs were extracted and grouped by life expec-
tancy category. Findings were aggregated into pooled ORs and 95% CIs and meta-analyzed 
by life expectancy category.
Main outcomes and measures: The primary outcome was SM utilization within the last 
5 years. Life expectancy factors included number of comorbidities, Charlson Comorbidity Index 
(CCI), activities of daily living, instrumental activities of daily living, self-reported health status 
and 5-year prognostic indices.
Results: Of 2,606 potential titles, we identified 25 meeting the inclusion criteria (comorbidity: 
eight studies, functional status: 11 studies and health/prognostic status: 13 studies). Women 
with higher CCI scores had decreased SM utilization (pooled OR: 0.75, 95% CI: 0.67–0.85), 
but increased absolute number of comorbidities were weakly associated with increased SM 
utilization (pooled OR: 1.17, 95% CI: 1.00–1.36). Women with more functional limitations 
had lower SM use odds than women with no limitations (pooled OR: 0.72, 95% CI: 0.62–0.83). 
Screening utilization odds were lower among women with poor vs excellent health (pooled 
OR: 0.85, 95% CI: 0.74–0.96).
Conclusion: Greater CCI score, functional limitations and lower perceived health were associ-
ated with decreased SM use, whereas higher absolute number of comorbidities was associated 
with increased SM use. SM guidelines should consider these factors to improve assessments 
of potential benefits and harms in older women.
Keywords: screening mammography, comorbidity, functional limitations, health status, 
meta-analysis
Introduction
More than 50% of new invasive breast cancer cases diagnosed each year in the US 
occur among older women – women ages 65 years or older.1 The increasing life 
expectancy of women in the US and attendant rise in the absolute number of breast 
cancer cases in older women will likely lead to an increasing absolute number of 
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mammograms performed in the $65 age group.2 In 2010, 
the United States Centers for Disease Control and Prevention 
estimated that older women reported the highest prevalence 
of mammography use within the past 2 years.3 However, the 
US Preventive Services Task Force (USPSTF) currently does 
not recommend screening mammography (SM) in women 
ages 75 or older due to insufficient evidence.4 Although older 
women have a higher risk of breast cancer and lower risk of 
false-positive mammography results than younger women, 
their shorter life expectancy decreases the potential benefits 
of screening.4–6
A recent review concluded that screening for breast 
cancer is most appropriate for women with a life expectancy 
of at least 10 years.7 Because the full benefit of screening is 
only realized with reduction in mortality, numerous studies 
have accounted for life expectancy factors to better identify 
the margin of benefit a woman might expect from undergo-
ing screening.3,7–10 To date, comorbidity burden, functional 
status and self-reported heath are the strongest predictors 
of life expectancy.11–14 However, the current guidelines for 
SM do not account for life expectancy factors other than 
chronological age.4,15
In light of the current demographic, epidemiologic and 
policy environment, it is important to understand the extent 
to which the current practice of SM is targeted to healthy 
older women and avoided in older women with limited life 
expectancy. In this review, we reported the results of a sys-
tematic review and meta-analysis of the literature of studies 
assessing mammography screening utilization rates of older 
women in relation to age, functional limitations and health 
status including but not limited to comorbidity. The main 
objective of this review was to outline the current practices 
that exist for SM utilization in older women and the associa-
tion between screening and life expectancy factors in order 
to help guide future SM guidelines.
Methods
This systematic review and meta-analysis has a published 
protocol16 and is registered with PROSPERO with the reg-
istration number CRD42016032661. A PRISMA checklist 
is included in Table S1. The study is covered under an insti-
tutional review board (IRB) with exempt status submitted 
and approved by the IRB of University of California, San 
Francisco.
Search strategy and selection criteria
We performed a systematic search of the literature using 
Medline (using PubMed interface), Embase and Web of 
Science (January 1, 1991–March 1, 2016) to identify relevant 
studies. “Breast neoplasms” was combined with the permuta-
tions, variations and abbreviations of the relevant Medical 
Subject Headings (MeSH) keywords and non-MeSH key terms 
for mammography, age, health status and comorbidity, includ-
ing cardiovascular diseases, comorbidity, cognition disorders, 
diabetes mellitus, functional limitation, health status, myo-
cardial infarction and stroke. Complete search strategies 
are provided in the “Supplementary materials” section.
The broad criteria for this review allowed for the evalu-
ation of multiple study designs published in English. The 
inclusion criteria were as follows: i) women aged 65 years 
or older in the US, ii) assessment of women’s comorbidity 
(either as a specific condition or as a summary score), func-
tional impairments and/or health status and iii) an outcome 
measure that addresses recent SM utilization. Additional 
studies were obtained through citations of review articles 
or contacting breast cancer screening experts regarding any 
unpublished articles that may be suitable for inclusion in the 
systematic review. Case reports were excluded. Data were 
extracted from the full-text article.
Most, if not all, of the target population was Medicare 
beneficiaries, with SM covered based on policy changes 
implemented in 1991.17 At that time, Medicare Part B medical 
insurance, for which most women become eligible when they 
turn 65 years, covered the full cost of annual mammography 
for all women aged 40 or older.2,4 To account for this Medi-
care policy change, we excluded studies evaluating screening 
utilization prior to 1991.17 Women eligible for Medicare ages 
65–74 years are near the upper limit of the USPSTF primary 
SM guidelines (age 74 years), and USPSTF guidelines note 
that data are currently inconclusive to provide screening 
recommendations for women ages 75 or older.18
Quality assessment and data extraction
To evaluate the quality of included studies, we used the 
Newcastle–Ottawa Scale (NOS) and Cochrane Collabora-
tion Risk of Bias (CCRB) tool19,20 to evaluate observational 
studies and clinical trials, respectively. The NOS measures 
the methodological quality of observational studies, giving 
predefined criteria, some of which have to be further speci-
fied based on topic. We specified these criteria in a consen-
sus meeting with the authors (Tables S2A and S2B) before 
assessing the studies.
Studies were assessed for quality of selection (represen-
tativeness, selection of controls, ascertainment of exposure), 
comparability (adjustment for confounding) and outcome 
or exposure (assessment of outcome/exposure, length and 
adequacy of follow-up) independently by two authors (JD 
and TA). Measures of age, socioeconomic status (such as 
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race, education, income), health insurance and number of 
physician visits were identified as important confounders. 
Cohort and case–control studies could earn a maximum of 
9 points, and cross-sectional and randomized clinical trials 
could earn a maximum of 10 points. Studies with scores of 
6–8 points were considered to be of moderate-to-good study 
quality, and scores of $9 were deemed excellent. All studies 
were summarized irrespective of quality score.
A data extraction form was used to collect study char-
acteristics, including type of study, number of participants, 
length of follow-up, exposure(s), outcome(s) and quality 
assessment. Exposures logged in this form were life expec-
tancy factors, including comorbidity scales or specific 
diseases considered, functional limitation scales used and 
measures of health status. The primary outcome was SM 
utilization, defined as SM occurring within the last 1–5 years. 
We extracted ORs and corresponding 95% CIs from most 
studies, with some studies providing risk ratios or propor-
tions of utilization. Quantitative results were extracted 
from text and tables, choosing preferably those adjusted 
for important confounders. Two authors (JD and TA) 
independently performed study quality assessment and data 
extraction. Discrepancies were discussed and resolved by 
the review team.
Qualitative synthesis and meta-analysis
We conducted a qualitative synthesis to describe the find-
ings of included studies, explore associations of interest 
and examine the quality of the studies and robustness of 
the systematic review. Study findings were separated into 
the four exposure categories: comorbidity (measured using 
an absolute count, Charlson Comorbidity Index [CCI] and 
individual disease conditions), functional limitations (activi-
ties of daily living [ADLs], instrumental activities of daily 
living [IADLs]), health status and prognostic status. For each 
exposure, we aggregated study findings to perform meta-
analyses assessing the overall magnitude of the association 
with recent SM utilization. Pooled ORs and corresponding 
95% CIs were reported. Given the variation in measurement 
of exposures, we stratified our findings to address study 
heterogeneity. Heterogeneity was measured using I2 values 
and Cochran’s Q statistic. Pooled results were analyzed using 
random–effects models to control for heterogeneity.
We also performed sensitivity analyses to examine 
potential publication bias including jackknife analyses21 and 
reported these findings in addition to the primary study findings 
and subgroup analyses.22 We also performed meta-regression 
to understand how study traits contributed to heterogeneity 
of pooled effect estimates.23,24 The meta-analysis results are 
graphically displayed using forest plots.22 All analyses were 
performed using STATA 13 (StataCorp LP, College Station, 
TX, USA).
Results
Study characteristics, including number of subjects, age 
range, years of data accrual, study design, assessment of 
outcome and assessment of exposure, are summarized in 
Table 1. We tabulated the full Newcastle–Ottawa findings 
of individual studies for descriptive purposes (Tables S2A 
and S2B). Full descriptive results by exposure type are found 
in Tables S3–S5.
Literature search
We identified 2,606 potentially relevant titles through 
PubMed, Embase and Web of Science (refer PRISMA flow-
chart in Figure 1). After excluding titles that did not report 
i) SM utilization and ii) comorbidity, health status and/or 
functional status and iii) original research that did not include 
(d) populations from the US, (e) SM utilization prior to 1991 
and (f) results for women ,65 years old, we identified 142 
studies published between January 1, 1991, and March 31, 
2016. After review of abstracts, we excluded 95 articles that 
did not meet the inclusion criteria. After reviewing 47 full-text 
articles,17,25–70 25 studies were included in the review, 
published between 1996 and 2016: there were ten cohort 
studies29,31,32,39,40,42,56,63,64,68 and 15 cross-sectional studies.17,27, 
33,36,37,44,46,51,52,59–62,65,69 No case–control studies were found, 
which is likely due to the highly common outcome of screen-
ing utilization. Characteristics of included studies are given 
in Table 1. Since three studies did not include ORs, only 22 
of the 25 studies were included in the meta-analysis.
Quality assessment
All of the studies used a combination of surveys, Medicare 
insurance claims data and/or medical records to examine 
associations between the predictor(s) – comorbidity, func-
tional status or health status – and the outcome, mammog-
raphy utilization. Based on the quality assessment using the 
NOS (no clinical trials were included),19 all studies were 
found to be of moderate to excellent quality, despite several 
studies using self-reported outcome assessment.
estimates of the effect of the comorbidity 
on utilization of SM
A full list of comorbidities measured in each study can 
be found in Table S3A–C. Eight studies measured the 
association of comorbidity with SM utilization, with 
four studies using an unweighted number of comorbid 
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conditions’ measure32,37,59,71 and four studies using the CCI 
(Figure 2).44,51,64,69 The pooled result showed no signifi-
cant association between comorbidity and SM utilization 
(OR: 0.94, 95% CI: 0.80–1.10). However, when stratified by 
comorbidity measurement, increased comorbidity measured 
using CCI was associated with decreased SM utilization 
(OR: 0.75, 95% CI: 0.67–0.85), while increased absolute 
number of comorbidities was weakly associated with 
Table 1 Characteristics of studies identified in literature search
Source Number of 
subjects
Age range, 
years
Accrual 
years
Study design Assessment of 
comorbidity/functional 
status/health status
Assessment of 
mammography 
utilization
Outcome(s)
Ives et al42 2,175 65–79 1991–1992 Cohort 
(prospective)
Medicare claims Medicare claims $1 screening 
in 2 years
Kiefe et al44 1,764 $50 1995 Cross-sectional Medical records review Medical records 
review
$1 screening 
within 2 years
Blustein et al29 2,352 $75 1991–1992 Cohort 
(retrospective)
Self-reported Medicare claims $1 screening 
within 2 years
wright et al69 526 $70 1992–1993 Cross-sectional Self-reported Self-reported $1 screening 
within 2 years
Barr et al27 309 $65 2000 Cross-sectional Self-reported Self-reported $1 screening 
within 2 years
Scinto et al63 844 $65 1990–1995 Cohort 
(prospective)
Self-reported, Medicare 
claims
Medicare claims $1 screening 
within 5 years
Caplan33 – 50–69
$70
1991–1992
1997–1998
Cross-sectional Self-reported Self-reported $1 screening 
within 2 years
Heflin et al37 2,225 $65 1992 Cross-sectional Self-reported Self-reported $1 screening 
within 2 years
Harrison et al36 10,000 $65 1993–1997 Cross-sectional Medicare claims Medicare claims $1 screening 
within 5 years
Schootman and 
Jeffe62
4,477 $40 1996 Cross-sectional Self-reported Self-reported $1 screening 
within 1 year
Schonberg et al59 882 $80 2000 Cross-sectional Self-reported Self-reported $1 screening 
within 2 years
walter et al17 3,988 $70 2000–2001 Cross-sectional Self-reported Self-reported $1 screening 
within 2 years
Bynum et al31 722,310 $65 2000–2001 Cohort 
(retrospective)
Medicare claims Medicare claims $1 screening 
within 2 years
Holt et al39 5,461 $65 1998–2002 Cohort 
(retrospective)
Self-reported Self-reported, 
Medicare claims
$1 screening 
within 1 year
Thorpe et al65 3,655 $65 1999–2001 Cross-sectional Self-reported Self-reported $1 screening 
within 2 years
Mcbean and Yu51 99,438 $65 1997–1998 Cross-sectional Medicare claims Medicare claims $1 screening 
within 2 years
Schonberg et al61 4,683 $65 2005 Cross-sectional Self-reported Self-reported $1 screening 
within 2 years
williams et al68 4,222 $65 2002–2004 Cohort 
(retrospective)
validated measures Self-reported $1 screening 
within 2 years
Mehta et al52 4,312 $70 2002 Cross-sectional Interview Medicare claims $1 screening 
within 2 years
Caban et al32 4,610 $65 2004–2005 Cohort 
(retrospective)
Self-reported Self-reported $1 screening 
within 1 year
Reyes-Ortiz 
et al56
1,272 $75 2004–2005 Cohort 
(retrospective)
Self-reported Self-reported $1 screening 
within 2 years
Koya et al46 4,836 $65 2002 Cross-sectional Self-reported Self-reported $1 screening 
within 1 year
Tan et al64 716,279 $75 2006–2007 Cohort 
(retrospective)
Medical record, claims Medicare claims $1 screening 
within 2 years
Schonberg et al60 2,266 $75 2008, 2010 Cross-sectional Self-reported Self-reported $1 screening 
within 2 years
Hubbard et al40 49,775 #65 2005–2010 Cohort 
(retrospective)
Medicare claims Medicare claims $1 screening 
within 2 years
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increased SM utilization (OR: 1.17, 95% CI: 1.00–1.36). 
Meta-regression results indicated that studies measuring 
comorbidity using CCI showed significantly lower SM 
utilization (pooled OR: 0.64, 95% CI: 0.50–0.82). Jackknife 
analyses showed that removal of McBean et al’s study and 
the 2004 Schonberg et al’s study, the two studies with the 
most extreme results, from CCI and absolute number of 
comorbidities groups, respectively, led to insignificant 
decreases in study heterogeneity and no marked change in 
the summary estimates.
In addition, nine studies measured individual comor-
bid conditions and their association with SM utilization 
(Table S3C).29,32,38,42,44,52,56,60,65 Physical conditions measured 
included hypertension, diabetes, lung disease, cancer, 
arthritis, myocardial infarction, stroke, heart disease and 
hip fracture. Mental conditions measured included cog-
nitive impairment, Alzheimer’s disease, depression and 
psychological distress. In pooled analyses, individual 
comorbid conditions were not significantly associated with 
SM utilization (OR: 0.97, 95% CI: 0.89–1.06; Figure S1). 
When stratified by type of condition, neither physical condi-
tions (OR: 1.03, 95% CI: 0.93–1.14) nor mental conditions 
(OR: 0.85, 95% CI: 0.72–1.01) were significantly associated 
with SM utilization.
Figure 1 PRISMA flowchart of studies included.
Note: Copyright: © 2009 Moher et al. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-
analyses: the PRISMA statement. PLoS Med 6(7):e1000097. doi: 10.1371/journal.pmed1000097.
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estimates of the effect of functional 
status on utilization of SM
Ten studies measured the effect of functional limitations 
on SM utilization (Figure 3), with three studies measuring 
functional limitations in multiple ways. Five studies mea-
sured ADLs,29,33,42,62,63 five studies measured IADLs32,37,42,56,59 
and three studies used a scale incorporating both IADLs 
and ADLs.32,59,69 Overall, functional limitations were asso-
ciated with decreased SM utilization (pooled OR: 0.72, 
95% CI: 0.62–0.83). Of the five studies measuring ADLs, 
three calculated ORs, showing a significant pooled effect of 
higher number of ADLs on decreased SM utilization (pooled 
OR: 0.55, 95% CI: 0.35–0.85) in Figure 3. Two studies reported 
chi-square results comparing SM utilization by ADL status 
(yes/no), with both studies showing a significant difference in 
screening utilization among women experiencing ADL limita-
tions compared to women with no ADL limitations.33,63
Among the four studies measuring IADLs, the pooled 
result showed that higher numbers of IADLs were associ-
ated with decreased SM utilization (pooled OR: 0.79, 95% 
CI: 0.64–0.98). Three studies measuring IADL limita-
tions in conjunction with ADL limitations found inverse 
associations.32,59,69 Pooled results indicated that ADL limita-
tions or IADL dependency led to decreased SM utilization 
(pooled OR: 0.72, 95% CI: 0.57–0.91).
In jackknife analyses, removal of Schootman et al long-
term ADLs and long-term IADLs and Caban et al findings led 
to study heterogeneity in ADL (P=0.674), IADL (P=0.106) 
and ADL/IADL (P=0.683) groups, respectively, being no 
longer statistically significant. However, the pooled estimate 
still had significant study heterogeneity and did not change 
appreciably despite removal of these studies (P=0.003). 
Meta-regression analyses found no significant predictors of 
study heterogeneity.
estimates of the effect of health status, 
life expectancy or prognosis on utilization 
of SM
Nine studies measured the association of health status on 
screening utilization, with eight studies measuring perceived 
general health29,32,39,46,60,61,69 and two studies measuring health 
status using the Short Form-12 (SF-12) survey (Table S5).17,27 
The pooled result shown in Figure 4 demonstrated that lower 
perceived health was associated with lower SM utilization 
(pooled OR: 0.80, 95% CI: 0.69–0.93). Jackknife analyses 
showed no significant decrease in study heterogeneity, and 
meta-regression analyses did not find significant predictors 
of study heterogeneity.
Five studies measured prognostic index or life expectancy 
measures against utilization of SM (Table S4).31,46,60,63,68 
Figure 2 Forest plot of effect of comorbidity on SM utilization by study and measure type.
Note: weights are from random-effects analysis.
Abbreviations: SM, screening mammography; eS, effect size; CCI, Charlson Comorbidity Index.
????????????????????
????????
?????????????????????????????????
?????????????????????????
???
????????????????????????????
???
?????
???????????
?????????
???
?????????????????????
???????????????????
?????
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????
???????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????
????????????????
??? ? ??
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
16
3.
8.
74
 o
n 
25
-M
ay
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Interventions in Aging 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1993
Screening mammography use in older women
The pooled effect of the three studies shown in Figure 4 mea-
suring life expectancy using regression showed a nonsignifi-
cant inverse association between life expectancy index score 
and SM utilization (pooled OR: 0.73, 95% CI: 0.53–1.00).
Discussion
Meta-analysis of the studies addressing life expectancy 
factors and SM utilization revealed that older American 
women with higher numbers of functional limitations, 
higher CCI score and lower perceived health are less likely 
to undergo routine SM. Prognostic indices, absolute number 
of comorbidities and specific disease conditions were not 
significantly associated with SM utilization. These observa-
tional studies provide a means to understanding how different 
measures of life expectancy affect SM utilization.
While increased CCI score was associated with a decrease 
in SM, the absolute number of comorbidities showed a con-
flicting, weak positive association with SM utilization. It is 
possible that having more comorbid conditions increased 
women’s contact with their health care provider, leading to 
a greater likelihood of using preventive care.32,37 Conversely, 
one study measuring CCI showed no indication that physi-
cians had advocated for cancer screening in the population 
of individuals with diabetes.51 Other studies noted that there 
is little time in the primary care clinic to estimate each indi-
vidual’s candidacy for screening, especially older patients 
with multiple medical problems, which might lead physicians 
to screen everyone to avoid confusion with recommenda-
tions or medicolegal consequences.17,37,59 The conflicting 
results show that more studies need to be conducted to 
determine who should receive SM and how comorbidity 
burden should factor into a provider’s assessment of who 
is eligible for SM.
Studies consistently indicated that greater numbers of 
functional limitations decreased SM utilization.29,32,37,42,56,59,62,69 
Studies using scales incorporating ADL limitations (ie, need-
ing help with activities such as showering, dressing, getting 
in and out of bed/chairs, etc.) showed particular pronounced 
effects,29,42,62 which one study suggested could indicate that 
access factors, such as fewer resources and social supports 
to facilitate travel to mammography facilities, may lead to 
lower utilization rates.29 It is therefore possible that women 
with ADL limitations may need more support to receive mam-
mography utilization. Another study indicated that the strong 
association found between ADL and IADL (ie, needing help 
with everyday household chores, shopping and overall getting 
Figure 3 Forest plot of effect of functional limitations on SM utilization by study and measure type.
Note: weights are from random-effects analysis.
Abbreviations: SM, screening mammography; eS, effect size; ADLs, activities of daily living; IADLs, instrumental activities of daily living.
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around) dependence and mammography screening might be 
indicative of providers considering life expectancy when refer-
ring women to SM.69 However, the fact that the finding did not 
occur across other measured preventive screenings makes this 
theory questionable and requires further investigation.
Poorer self-rated health was also found to be associated 
with decreased screening utilization, despite some conflict-
ing findings. In one study, pain and discomfort, a potential 
indicator of poorer health, was a common reason why women 
might decide not to screen.32 Conversely, a study done by 
Walter et al showed that older women with poorer health 
status, measured using the Medical Outcomes Study 12-item 
Short Form Physical Summary Scale (SF-12), did not avoid 
screening. Although Walter et al did not have mortality 
follow-up information on the sample, there is strong evidence 
that life expectancy is limited in women with worst health 
status measured by the SF-12.17
Pooled analysis of prognostic index scores found no sig-
nificant association with SM utilization, even though some 
individual studies had significant findings. Koya et al found 
mammography use significantly associated with 4-year mortal-
ity risk and not age alone, attributing their finding to including 
age, comorbidity and functional status in their measurement 
of mortality risk.46 They hypothesized that the association 
means clinicians are skilled at identifying predictors of life 
expectancy in older individuals.46 However, findings from 
other included studies seem to contradict this theory.60,68
Findings from these studies show that functional limita-
tions and comorbidities when measured using the CCI are 
associated with decreased SM utilization, while absolute 
number of comorbidities was weakly associated with 
increased screening utilization. When discussing SM with 
older women, providers should ask questions or consult 
medical records to learn more about these life expectancy 
factors to better assess the potential benefit older women 
might receive from undergoing SM. Decision aids have 
been developed in breast cancer screening to measure key 
comorbidity and functional measures, though none have been 
widely implemented.72,73 While more research is necessary to 
further understand the importance of life expectancy in mea-
suring harms and benefits of SM, these findings indicate that 
providers may be weighing more than just age when discuss-
ing continuing SM with an older woman. Further assessment 
of current clinical recommendations and determination of 
eligibility for SM could lead to more accurately tailored 
screening referrals.
Figure 4 Forest plot of effect of health status and prognostic score on SM utilization by study and measure type.
Note: weights are from random-effects analysis.
Abbreviations: SM, screening mammography; eS, effect size; SF-12, Short Form-12; PCS, physical component summary score; MCS, mental component summary score.
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Strengths and limitations of studies and 
analysis
Our systematic review/meta-analysis had key strengths, such 
as incorporating searches from three major research publica-
tion databases ensuring full capture of the literature on life 
expectancy factors and SM utilization in older women. The 
use of quality assessment tools allowed us to quantitatively 
rate the quality of the studies included in our analyses. 
In addition, the use of stratification to clearly review the 
life expectancy factors ensured a limited degree of study 
heterogeneity when measuring our various exposures and 
SM utilization. Our study also was able to leverage meta-
regression in sensitivity analyses to learn more about how 
different study features contributed to heterogeneity found 
in pooled results from meta-analyses.
Our review also had several limitations. The 20-year 
timespan of systematic review could lead to varied results due 
to secular trends, but examining the study results by year does 
not indicate that a trend exists. While this might account for 
some variation in the results, the lack of significant changes in 
screening mammography guidelines or public outreach within 
this older age group make any difference in effects due to 
secular trends minimal. Of the 25 studies included in our anal-
ysis, 17 relied on self-reported information for measurement 
of the exposure, while 16 relied on self-reported information 
to measure SM utilization. This raises concerns about recall 
bias, particularly when citing screening utilization within the 
last 2–5 years. Furthermore, self-reported health status is not 
a precise measurement of an individual’s health, as it uses a 
Likert scale to assess health at the instance of interview, which 
might not represent an individual’s overall health outside 
the clinical environment. Studies that ascertained screening 
utilization through insurance claims29,31,36,39,40,42,51,52,63,64 were 
unable to distinguish between mammograms undertaken for 
screening and diagnostic purposes. However, it is reason-
able from a clinical perspective to assume that the majority 
were screening procedures, since diagnostic procedures are 
performed only when a woman presents with symptoms of 
breast cancer.29,51,52 The inability to distinguish the two types 
of mammography might lead to the measured population 
being slightly sicker than the normal SM population, which 
would lead to an overestimate of association.
More than half of the studies included were cross-
sectional by design, which restricts the ability to ensure 
temporality of the exposure/outcome relationship. Despite 
this concern, all but two studies were of moderate to excel-
lent study quality based on our cross-sectional study-specific 
quality assessment using the Newcastle–Ottawa Survey.
Conclusion
Studies have shown that the primary determinant of screen-
ing with mammography, regardless of age, is a physician’s 
recommendation.59,74–76 It is therefore critical that the guide-
lines be updated to reflect the importance of characteristics 
such as the presence of severe functional dependencies in 
ADLs and severe comorbidity as caused by conditions such as 
end-stage renal disease and severe dementia in concert with 
clinical judgment to estimate an individual’s potential risks 
and benefits from screening rather than basing screening deci-
sions on age alone. This systematic review and meta-analysis 
shows that consideration of functional status and comorbidity 
might be occurring in practice but still needs to be further 
weighed in SM recommendations, and targeted interventions 
are needed to facilitate precision cancer screening.
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